# Alleviant ALLAY-HFrEF Study

Study · id `cardio:ct-nct06812533` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06812533](<https://clinicaltrials.gov/study/NCT06812533>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06812533

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 350 participants.

## Technical summary

Registry record NCT06812533. Randomized; double masking; primary purpose treatment. Start 2025-03-10 (actual); primary completion 2028-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 350 participants (planned count; ClinicalTrials.gov record NCT06812533, source copy `cardio:ctgov-nct06812533-2026-10-06`, retrieved 2026-10-26)
- Started: 2025-03-10 (actual) (ClinicalTrials.gov record NCT06812533, source copy `cardio:ctgov-nct06812533-2026-10-06`, retrieved 2026-10-26)
- Primary completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT06812533, source copy `cardio:ctgov-nct06812533-2026-10-06`, retrieved 2026-10-26)
- Completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT06812533, source copy `cardio:ctgov-nct06812533-2026-10-06`, retrieved 2026-10-26)
- Countries: United States; Australia; Belgium; Canada; Georgia; Greece; Israel; New Zealand; Poland; Serbia; Spain (ClinicalTrials.gov record NCT06812533, source copy `cardio:ctgov-nct06812533-2026-10-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06812533-2026-10-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Alleviant ALLAY-HFrEF Study
- Condition: Heart Failure
- Intervention (Device): Alleviant ALV1 System
- Intervention (Other): Sham-Control
- Lead sponsor: Alleviant Medical, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: 8afa101451c7aa8b2c460f988e45122fdb2dbee0132c2b2db3d616ebc1d4a1fd
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
